七月 2026
- Home
- Evox Therapeutics
七月 2026的Evox Therapeutics市场份额分析
Rewriting the narrative of neurodegenerative disease Next-generation gene editing addressing the root cause of neurodegeneration Our Mission We are committed to expanding the reach of genetic medicine into the brain and transforming the treatment landscape for severe neurodegenerative diseases. Evox’s exosome-based therapies are designed to deliver safer, more effective and commercially scalable treatments, drawing on ... Read more
Evox Therapeutics(包含公司地区分支机构)
查看更多网站流量和参与度信息- evoxtherapeutics.com
Evox Therapeutics收入截至 七月 2026为 10M - 15M
Evox Therapeutics主要域名产生的收入
3 年中Evox Therapeutics主要域名的收入
Evox Therapeutics主要域名的收入
Evox Therapeutics热门域名的总访问量
了解Evox Therapeutics市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Evox Therapeutics热门域名的平均访问时长
分析Evox Therapeutics参与度指标。
过去 3 个月的平均访问时长
子公司明细
Evox Therapeutics热门域名的平均页面浏览量
了解Evox Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Evox Therapeutics 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻eXmoor Pharma Concepts Ltd partnered with Evox Therapeutics Ltd. on Jul 21st '26.Bristol, UK - 21 July 2026: eXmoor Pharma ('eXmoor'), the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Evox Therapeutics ('Evox') have completed a technology transfer programme for Evox's exosome-enabled gene editing technology and specifically its MSH3-targeted programme for the treatment of Huntington's disease.
七月 21, 2026阅读更多
新闻Evox Therapeutics Ltd partnered with Rett Syndrome Research Trust on Feb 26th '26.OXFORD, United Kingdom, February 26, 2026 - Evox Therapeutics Ltd ("Evox" or the "Company"), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the Company's ExoEdit(R) exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome.
二月 26, 2026阅读更多
新闻Evox Therapeutics Ltd promoted Per Lundin to Chief Executive Officer on Apr 29th '24.Oxford, U.K. April 29, 2024 - Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer (CEO) of the Company and will be appointed to its Board of Directors.
四月 29, 2024阅读更多
查看 Evox Therapeutics 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
